Trial Profile

A Phase 1/2 Open-label Study to Evaluate the Safety and Efficacy of MK-1200 in Participants With Advanced Solid Tumors

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 04 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MK 1200 (Primary) ; Dexamethasone; Neurokinin 1 receptor antagonists; Serotonin 3 receptor antagonists
Indications Adenocarcinoma; Biliary cancer; Gastric cancer; Oesophageal cancer; Pancreatic ductal carcinoma; Solid tumours
Focus Adverse reactions
Sponsors Merck Sharp & Dohme

Most Recent Events

27 Jun 2025 Status changed from active, no longer recruiting to completed.
09 Apr 2025 The timeframe for the primary endpoint 'Number of Participants Who Experience One or More AEs' was changed from 34 months to 6 months, and for 'Number of Participants Who Discontinue Study Intervention Due to an AE' from 34 months to 15 months.
09 Apr 2025 Planned End Date changed from 3 Jan 2026 to 18 Jun 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com